Area of research
Genetics · Cancer Research
Research interest
Research interests include Glioma Diagnosis and Treatment, Cancer, Hypoxia, and Metabolism, Brain Metastases and Treatment, and Radiopharmaceutical Chemistry and Applications.
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses
Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAM
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium
Risk Factors, Indications, and Effectiveness of Cerebrospinal Fluid Diversion in Patients With High-Grade Glioma–Associated Hydrocephalus: A Systematic Review and Meta-Analysis
Value of Engagement in Digital Health Technology Research: Evidence Across 6 Unique Cohort Studies
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors
A Randomized, Double-blind, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Mutant IDH1/2 Diffuse Glioma (INDIGO): Analysis of Health-related Quality of Life, Neurocognition and Seizures (PL5.003)
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022
QOL-26. A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT <i>IDH1/2</i>DIFFUSE GLIOMA (INDIGO): ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE, NEUROCOGNITION AND SEIZURES
Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluid
LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT <i>IDH1</i> OR <i>IDH2</i> DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY
A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma
Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies
Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Ivosidenib in Isocitrate Dehydrogenase 1<i>–</i>Mutated Advanced Glioma
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients
MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas
Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas
Evolving Treatments for Primary Central Nervous System Lymphoma
A multiprotein supercomplex controlling oncogenic signalling in lymphoma
Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy
The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas
ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION